Effectiveness of Desmanthus virgatus Leaf Ethyl Acetate Extract and Antiviral Drugs as Antirabies Based on In Silico Study
DOI:
10.29303/jpm.v20i4.9024Published:
2025-06-27Issue:
Vol. 20 No. 4 (2025): Special IssueKeywords:
Antiviral Drugs; Desmanthus virgatus; Flavonoid Glycosides; Molecular DockingRabies VirusArticles
Downloads
How to Cite
Downloads
Metrics
Abstract
Rabies is a deadly viral disease that has no effective therapy after clinical symptoms appear. This study aims to evaluate the antirabies potential of the dominant compounds in the ethyl acetate extract of Desmanthus virgatus leaves, as well as several antiviral drugs, through an in silico approach. The extract was obtained through maceration and partitioning methods using ethyl acetate solvent, then analyzed using LC-MS, which identified 182 secondary metabolite compounds, and ten dominant compounds were selected for further analysis. These compounds, along with seven antiviral drugs, were docked against the rabies virus glycoprotein (PDB ID: 6LGX) using AutoDockTools 4.2.6 software. The docking results were analyzed based on the values of binding affinity, inhibition constant (Ki), and interaction with active amino acid residues. Quercitrin and quercimeritrin were the dominant flavonoid glycosides in the ethyl acetate extract of D. virgatus leaves that showed binding affinity values of -8.45 kcal/mol and -8.10 kcal/mol, respectively. In addition, bictegravir and tegobuvir showed binding affinity values of -9.17 kcal/mol and -9.05 kcal/mol, respectively. Four compounds indicated potential as antirabies drugs. Pharmacokinetic feasibility tests using Lipinski parameters showed that most of the dominant compounds violated one or more parameters, especially the number of hydrogen bond donors/acceptors and molecular weight. However, such violations were also found in some antiviral drugs that have been used, such as remdesivir and darunavir. These results suggest that D. virgatus leaf extracts contain compounds with promising potential antirabies activity and deserve further investigation through in vitro and in vivo tests.
References
A. R. Fooks et al., “Rabies,” Nat Rev Dis Primers, vol. 3, no. 1, p. 17091, Nov. 2017, doi: 10.1038/nrdp.2017.91.
C. H. Calisher and J. A. Ellison, “The other rabies viruses: The emergence and importance of lyssaviruses from bats and other vertebrates,” Travel Med Infect Dis, vol. 10, no. 2, pp. 69–79, Mar. 2012, doi: 10.1016/j.tmaid.2012.01.003.
S. Zhu and C. Guo, “Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential,” Viruses, vol. 8, no. 11, p. 279, Oct. 2016, doi: 10.3390/v8110279.
M. Y. Jane Ling et al., “Rabies in Southeast Asia: a systematic review of its incidence, risk factors and mortality,” BMJ Open, vol. 13, no. 5, p. e066587, May 2023, doi: 10.1136/bmjopen-2022-066587.
M. J. Schnell, J. P. McGettigan, C. Wirblich, and A. Papaneri, “The cell biology of rabies virus: using stealth to reach the brain,” Nat Rev Microbiol, vol. 8, no. 1, pp. 51–61, Jan. 2010, doi: 10.1038/nrmicro2260.
D. Kurup, C. E. Rupprecht, S. J. Scholand, C. Yankowki, and M. Schnell, “Glimpses into the past: New World contributions towards understanding the basic etiology, pathobiology and treatment of rabies,” in History of Rabies in the Americas: From the Pre-Columbian to the Present, Cham, Switzerland: Springer, 2023, pp. 15–41.
A. Tarantola, “Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure,” Trop Med Infect Dis, vol. 2, no. 2, p. 5, Mar. 2017, doi: 10.3390/tropicalmed2020005.
M. J. Warrell and D. A. Warrell, “Rabies: the clinical features, management and prevention of the classic zoonosis,” Clinical Medicine, vol. 15, no. 1, pp. 78–81, Feb. 2015, doi: 10.7861/clinmedicine.14-6-78.
V. Du Pont, R. K. Plemper, and M. J. Schnell, “Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses,” Curr Opin Virol, vol. 35, pp. 1–13, Apr. 2019, doi: 10.1016/j.coviro.2018.12.009.
A. Balkrishna, N. Sharma, D. Srivastava, A. Kukreti, S. Srivastava, and V. Arya, “Exploring the Safety, Efficacy, and Bioactivity of Herbal Medicines: Bridging Traditional Wisdom and Modern Science in Healthcare,” Future Integrative Medicine, vol. 3, no. 1, pp. 35–49, Mar. 2024, doi: 10.14218/FIM.2023.00086.
G. Mesa and J. Enrique, “Evaluación química y nutricional de plantas consumidas por pequeños rumiantes en ecosistemas secos del alto magdalena,” Ibagué Universidad del Tolima, 2011.
S. L. Badshah, S. Faisal, A. Muhammad, B. G. Poulson, A. H. Emwas, and M. Jaremko, “Antiviral activities of flavonoids,” Biomedicine & Pharmacotherapy, vol. 140, p. 111596, Aug. 2021, doi: 10.1016/j.biopha.2021.111596.
A. C. Jackson, “Current and future approaches to the therapy of human rabies,” Antiviral Res, vol. 99, no. 1, pp. 61–67, Jul. 2013, doi: 10.1016/j.antiviral.2013.01.003.
A. Subbaiyan et al., “In silico Molecular Docking Analysis Targeting SARS-CoV-2 Spike Protein and Selected Herbal Constituents,” J Pure Appl Microbiol, vol. 14, no. suppl 1, pp. 989–998, May 2020, doi: 10.22207/JPAM.14.SPL1.37.
N. Mahfoudhi, R. Ksouri, and S. Hamdi, “Nanoemulsions as potential delivery systems for bioactive compounds in food systems: preparation, characterization, and applications in food industry,” in Emulsions, Elsevier, 2016, pp. 365–403. doi: 10.1016/B978-0-12-804306-6.00011-8.
J. B. Harborne and C. A. Williams, “Advances in flavonoid research since 1992,” Phytochemistry, vol. 55, no. 6, pp. 481–504, Nov. 2000, doi: 10.1016/S0031-9422(00)00235-1.
A. Gomes, E. Fernandes, J. Lima, L. Mira, and M. Corvo, “Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids,” Curr Med Chem, vol. 15, no. 16, pp. 1586–1605, Jul. 2008, doi: 10.2174/092986708784911579.
W. F. Hodnick, E. B. MllosavljeviĆ, J. H. Nelson, and R. S. Pardini, “Electrochemistry of flavonoids,” Biochem Pharmacol, vol. 37, no. 13, pp. 2607–2611, Jul. 1988, doi: 10.1016/0006-2952(88)90253-5.
J. H. Zothantluanga and D. Chetia, “A Beginner’s Guide to Molecular Docking,” Sci Phytochem, vol. 1, no. 2, pp. 90–93, Dec. 2022, doi: 10.58920/sciphy01020037.
L. Patowary, M. Sarma, J. H. Zothantluanga, and D. Chetia, “Repurposing of FDA Approved Drugs Having Structural Similarity to Artemisinin Against PfDHFR-TS Through Molecular Docking and Molecular Dynamics Simulation Studies,” Curr Trends in Pharm Res, vol. 8, no. 2, 2022, [Online]. Available: www.dibru.ac.in/ctpr
J. H. Zothantluanga, S. K. Aswin, M. Rudrapal, and D. Cheita, “Antimalarial flavonoid-glycoside from acacia pennata with inhibitory potential against PfDHFR-TS: An in-silico study,” Biointerface Res Appl Chem, vol. 12, no. 4, pp. 4871–4887, Aug. 2022, doi: 10.33263/BRIAC124.48714887.
P. L. Kastritis and A. M. J. J. Bonvin, “On the binding affinity of macromolecular interactions: daring to ask why proteins interact,” J R Soc Interface, vol. 10, no. 79, Feb. 2013, doi: 10.1098/rsif.2012.0835.
A. K. Pandey and S. Verma, “An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease,” J Biomol Struct Dyn, vol. 40, no. 1, pp. 136–142, Jan. 2022, doi: 10.1080/07391102.2020.1809522.
V. A. Adhav and K. Saikrishnan, “The Realm of Unconventional Noncovalent Interactions in Proteins: Their Significance in Structure and Function,” ACS Omega, vol. 8, no. 25, pp. 22268–22284, Jun. 2023, doi: 10.1021/acsomega.3c00205.
M. A. H. Ismail, D. A. Abou El Ella, K. A. M. Abouzid, and A. H. Mahmoud, “Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives,” Bioorg Med Chem, vol. 20, no. 7, pp. 2455–2478, Apr. 2012, doi: 10.1016/j.bmc.2012.01.031.
J. M. Molina et al., “Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial,” Lancet HIV, vol. 5, no. 7, pp. e357–e365, Jul. 2018, doi: 10.1016/S2352-3018(18)30092-4.
Z. Xu, Z. Yang, Y. Liu, Y. Lu, K. Chen, and W. Zhu, “Halogen Bond: Its Role beyond Drug–Target Binding Affinity for Drug Discovery and Development,” J Chem Inf Model, vol. 54, no. 1, pp. 69–78, Jan. 2014, doi: 10.1021/ci400539q.
A. Madushanka, R. T. Moura, N. Verma, and E. Kraka, “Quantum Mechanical Assessment of Protein–Ligand Hydrogen Bond Strength Patterns: Insights from Semiempirical Tight-Binding and Local Vibrational Mode Theory,” Int J Mol Sci, vol. 24, no. 7, p. 6311, Mar. 2023, doi: 10.3390/ijms24076311.
L. Lins and R. Brasseur, “The hydrophobic effect in protein folding,” FASEB J, vol. 9, no. 7, pp. 535–540, Apr. 1995, doi: 10.1096/fasebj.9.7.7737462.
G. M. Ghiandoni and E. Caldeweyher, “Fast calculation of hydrogen-bond strengths and free energy of hydration of small molecules,” Sci Rep, vol. 13, no. 1, p. 4143, Mar. 2023, doi: 10.1038/s41598-023-30089-x.
S. K. Bardal, J. E. Waechter, and D. S. Martin, “Basic Principles and Pharmacodynamics,” in Applied Pharmacology, Elsevier, 2011, pp. 3–16. doi: 10.1016/B978-1-4377-0310-8.00001-4.
C. Herkenne et al., “In Vivo Methods for the Assessment of Topical Drug Bioavailability,” Pharm Res, vol. 25, no. 1, p. 87, Jan. 2008, doi: 10.1007/s11095-007-9429-7.
M. N. Martinez and G. L. Amidon, “A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals,” The Journal of Clinical Pharmacology, vol. 42, no. 6, pp. 620–643, Jun. 2002, doi: 10.1177/00970002042006005.
O. Pillai, A. B. Dhanikula, and R. Panchagnula, “Drug delivery: an odyssey of 100 years,” Curr Opin Chem Biol, vol. 5, no. 4, pp. 439–446, Aug. 2001, doi: 10.1016/S1367-5931(00)00226-X.
T. Rezai, J. E. Bock, M. V. Zhou, C. Kalyanaraman, R. S. Lokey, and M. P. Jacobson, “Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides,” J Am Chem Soc, vol. 128, no. 43, pp. 14073–14080, Nov. 2006, doi: 10.1021/ja063076p.
A. Alex, D. S. Millan, M. Perez, F. Wakenhut, and G. A. Whitlock, “Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space,” Medchemcomm, vol. 2, no. 7, p. 669, 2011, doi: 10.1039/c1md00093d.
G. Sampat, S. S. Suryawanshi, M. S. Palled, A. S. Patil, P. Khanal, and A. S. Salokhe, “Drug Likeness Screening and Evaluation of Physicochemical Properties of Selected Medicinal Agents by Computer Aided Drug Design Tools,” Advances in Pharmacology and Pharmacy, vol. 10, no. 4, pp. 234–246, Oct. 2022, doi: 10.13189/app.2022.100402.
M. Navia and P. Chaturvedi, “Design principles for orally bioavailable drugs,” Drug Discov Today, vol. 1, no. 5, pp. 179–189, May 1996, doi: 10.1016/1359-6446(96)10020-9.
T. A. Berger, B. K. Berger, and K. Kogelman, “Chromatographic Separations and Analysis: Supercritical Fluid Chromatography for Chiral Analysis and Semi-Preparative Purification,” in Comprehensive Chirality, Elsevier, 2024, pp. 355–393. doi: 10.1016/B978-0-32-390644-9.00013-5.
H. Herawati, R. N. A. Jabbar, dan Y. Oktanella, “Analisis pemberian serbuk jahe merah, kunyit, dan temulawak dengan metode in silico dan in vivo pada ayam broiler,” Jurnal Sain Veteriner, vol. 41, no. 1, pp. 98–111, Apr. 2023, doi: 10.22146/jsv.76111.
N. Idrees, E. Noor, S. Rashid, and F. T. Agama, “Role of topological indices in predictive modeling and ranking of drugs treating eye disorders,” Sci Rep, vol. 15, no. 1, p. 1271, Jan. 2025, doi: 10.1038/s41598-024-81482-z.
Z. Y. Ibrahim, A. Uzairu, G. A. Shallangwa, and S. E. Abechi, “Pharmacokinetic predictions and docking studies of substituted aryl amine-based triazolopyrimidine designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH),” Futur J Pharm Sci, vol. 7, no. 1, p. 133, Dec. 2021, doi: 10.1186/s43094-021-00288-2.
D. Rana, S. Salave, D. Khunt, and D. Benival, “Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease,” in Alzheimer’s Disease and Advanced Drug Delivery Strategies, Elsevier, 2024, pp. 47–60. doi: 10.1016/B978-0-443-13205-6.00018-2.
I. Klojdová, T. Milota, J. Smetanová, and C. Stathopoulos, “Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?,” Pharmaceuticals, vol. 16, no. 3, p. 362, Feb. 2023, doi: 10.3390/ph16030362.
Author Biographies
Syahrul Hendrawan, Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya
Cindy Ambarwati, Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya
Department of Chemistry, Faculty Mathematics and Natural Science, Universitas Negeri Surabaya, Surabaya, Indonesia
Tukiran Tukiran, Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya
Prof. Dr. Tukiran, M.Si.
Department of Chemistry, Faculty Mathematics and Natural Science, Universitas Negeri Surabaya, Surabaya, Indonesia
License
Copyright (c) 2025 Syahrul Hendrawan, Cindy Ambarwati, Tukiran Tukiran
This work is licensed under a Creative Commons Attribution 4.0 International License.
The following terms apply to authors who publish in this journal:
1. Authors retain copyright and grant the journal first publication rights, with the work simultaneously licensed under a Creative Commons Attribution License 4.0 International License (CC-BY License) that allows others to share the work with an acknowledgment of the work's authorship and first publication in this journal.
2. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., posting it to an institutional repository or publishing it in a book), acknowledging its initial publication in this journal.
3. Before and during the submission process, authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website), as this can lead to productive exchanges as well as earlier and greater citation of published work (See The Effect of Open Access).
